Low-Dose rIL-15 Protects from Nephrotoxic Serum Nephritis via CD8⁺ T Cells.

ABSTRACT: Rapid progressive glomerulonephritis (GN) often leads to end-stage kidney disease, driving the need for renal replacement therapy and posing a global health burden. Low-dose cytokine-based immunotherapies provide a new strategy to treat GN. IL-15 is a strong candidate for the therapy of immune-mediated kidney disease since it has proven to be tubular-protective before. Therefore, we set out to test the potential of low-dose rIL-15 treatment in a mouse model of nephrotoxic serum nephritis (NTS), mimicking immune complex-driven GN in humans. A single low-dose treatment with rIL-15 ameliorated NTS, reflected by reduced albuminuria, less tissue scarring, fewer myeloid cells in the kidney, and improved tubular epithelial cell survival. In addition, CD8⁺ T cells, a primary target of I

SUBMITTER: Mooslechner AA 

PROVIDER: S-EPMC9688325 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature